Summary

Visit our virtual booth and listen to our talk during the Cell & Gene Therapy Bioprocessing & Commercialization virtual event.

Our team

 Ashlee Propson 
 Field Application Specialist - AMERICAS 
About Ashlee Propson
Field Application Specialist - AMERICAS
Aucune information.
 Phyllis Martin 
 Sales Specialist - North East 
About Phyllis Martin
Sales Specialist - North East
Aucune information.
 Brian Bulsak 
 Sales Specialist - Mid-Atlantic 
About Brian Bulsak
Sales Specialist - Mid-Atlantic
Aucune information.
 Mathieu Porte 
 Bioproduction R&D Manager  
About Mathieu Porte
Bioproduction R&D Manager
Aucune information.

Talk: Next-Generation Transfection Reagent for Large Scale AAV Manufacturing

Transient transfection of suspension cells is the most commonly used production platform for AAV manufacturing.

However, this method shows some limitations in large scale bioreactors: inadequate transfection protocol, reduced transfection efficiency and lower productivity. To address this concern, we present data on the novel transfection reagent showing: i) increased AAV titers, ii) improved transfection protocol for large scale bioreactors and iii) reproducibility of viral titers at different production scale.

Presented by Mathieu Porte, R&D Production  Manager at Polyplus-transfection®

Talk Available on demande on the In Vivo Gene Therapy track for the duration of the virtual event

Our solutions for both protein and virus production

NEW! FectoVIR®-AAV: for Recombinant AAV virus production in suspension cells.

PEIpro® product range for a scalable viral vector production for Gene & Cell therapy.

FectoPRO® Transfection kit is specifically designed for enhanced Transient Gene Expression (TGE) in suspension CHO and HEK-293 cells in various serum-free media, using low DNA amount (< 1 µg/ml of cell culture).

General information

Registration link for virtual event: click here

 

Give your feedback!